ASCENTAGE-B (06855.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec6

Yabio Pharmaceuticals Presents Lisaftoclax Efficacy Data for Chronic Lymphocytic Leukemia

15:18

Dec4

Yashen Pharmaceuticals' Olverabatinib Granted FDA and EMA Phase III Clinical Trial Approval

23:58

Nov4

Ascentage Pharma to Present Bcl-2 Inhibitor Lisaftoclax Data at ASH Annual Meeting

01:32

Several Clinical Advances of Yabio's New Drugs Selected for ASH Annual Meeting

00:24

Aug27

Yashen Pharmaceuticals Approved Innovative Drug Lisatoclax and Initiated Global Phase III Clinical Trial Registration

06:26

Aug25

CICC Raises Target Price for Ascentage Pharma-B to HKD 105

02:48

Schedules & Filings

Schedules

Filings

Aug19

Earning Release(CST)

FY2025 Semi-Annual Earning Release

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 127.89 M, Net Income -323.3 M, EPS -0.9467

Mar27

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 83.46 M, Net Income -302.37 M, EPS -0.9679

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change